Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): State of the art and future perspectives

Autoimmunity Reviews

Volumn 12, Issue 1, 2012, Pages 38-43

  Cantarini, Luca ^a   Lucherini, Orso Maria ^a   Muscari, Isabella ^a   Frediani, Bruno ^a   Galeazzi, Mauro ^a   Brizi, Maria Giuseppina ^a   Simonini, Gabriele ^a   Cimaz, Rolando ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Amyloidosis; Autoinflammatory disorders; Interleukin (IL) 1 inhibition; TNFRSF1A gene; Tumor necrosis factor receptor associated periodic syndrome (TRAPS)

Indexed keywords

ADALIMUMAB; ADIPONECTIN; C REACTIVE PROTEIN; CANAKINUMAB; COLCHICINE; CYCLOSPORIN; ETANERCEPT; IMMUNOGLOBULIN FC FRAGMENT; INFLIXIMAB; INTERLEUKIN 6; LEPTIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SERUM AMYLOID A; THALIDOMIDE; TOCILIZUMAB; TUMOR NECROSIS FACTOR RECEPTOR;

ACUTE PHASE RESPONSE; BINDING SITE; CARDIOVASCULAR RISK; CHROMOSOME 12P; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG MEGADOSE; ENDOPLASMIC RETICULUM; ERYTHEMA; EXON; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HUMAN; HYDROGEN BOND; KIDNEY AMYLOIDOSIS; LIGAND BINDING; LINKAGE ANALYSIS; MUSCLE CRAMP; MYALGIA; OLIGOMERIZATION; PATIENT COMPLIANCE; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; QUALITY OF LIFE; RECURRENT FEVER; RELAPSE; REMISSION; REVIEW; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; T LYMPHOCYTE ACTIVATION; TANDEM REPEAT; TREATMENT RESPONSE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

ANIMALS; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I;

EID: 84866867382     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.07.020     Document Type: Review

References (52)

1. Dodé C., André M., Bienvenu T., Hausfater P., Pêcheux C., Bienvenu J., et al. French Hereditary Recurrent Inflammatory Disorder Study Group. The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2002, 46:2181-2188.
2. Aganna E., Hammond L., Hawkins P.N., Aldea A., McKee S.A., van Amstel H.K., et al. Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 2003, 48:2632-2644.
3. Aksentijevich I., Galon J., Soares M., Mansfield E., Hull K., Oh H.H., et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001, 69:301-314.
4. Cantarini L., Imazio M., Brucato A., Lucherini O.M., Galeazzi M. Innate versus acquired immune response in the pathogenesis of recurrent idiopathic pericarditis. Autoimmun Rev 2010, 9:436-440.
5. McDermott M.F., Aksentijevich I., Galon J., McDermott E.M., Ogunkolade B.W., Centola M., et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999, 97:133-144.
6. Masters S.L., Simon A., Aksentijevich I., Kastner D.L. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009, 27:621-668.
7. Dinarello C.A. Blocking interleukin-1β in acute and chronic autoinflammatory diseases. J Intern Med 2011, 269:16-28.
8. Williamson L.M., Hull D., Mehta R., Reeves W.G., Robinson B.H., Toghill P.J. Familial Hibernian fever. Q J Med 1982, 51:469-480.
9. McDermott M.F., Ogunkolade B.W., McDermott E.M., Jones L.C., Wan Y., Quane K.A., et al. Linkage of familial Hibernian fever to chromosome 12p13. Am J Hum Genet 1998, 62:1446-1451.
10. Nedjai B., Hitman G.A., Yousaf N., Chernajovsky Y., Stjernberg-Salmela S., Pettersson T., et al. Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008, 58:273-283.
11. Sarrauste de Menthière C., Terrière S., Pugnère D., Ruiz M., Demaille J., et al. INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res 2003, 31:282-285.
12. Chan F.K., Chun H.J., Zheng L., Siegel R.M., Bui K.L., Lenardo M.J. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000, 288:2351-2354.
13. Banner D.W., D'Arcy A., Janes W., Gentz R., Schoenfeld H.J., Broger C., et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993, 73:431-445.
14. Rebelo S.L., Bainbridge S.E., Amel-Kashipaz M.R., Radford P.M., Powell R.J., Todd I., et al. Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum 2006, 54:2674-2687.
15. Ravet N., Rouaghe S., Dodé C., Bienvenu J., Stirnemann J., Lévy P., et al. Clinical significance of P46L and R92Q substitutions in the tumor necrosis factor superfamily 1A gene. Ann Rheum Dis 2006, 65:1158-1162.
16. Tchernitchko D., Chiminqgi M., Galactéros F., Préhu C., Segbena Y., Coulibaly H., et al. Unexpected high frequency of P46L TNFRSF1A allele in sub-Saharan West African populations. Eur J Hum Genet 2005, 13:513-515.
17. Bazzoni F., Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996, 334:1717-1725.
18. Wajant H., Pfizenmaier K., Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003, 10:45-65.
19. Kimberley F.C., Lobito A.A., Siegel R.M., Screaton G.R. Falling into TRAPS-receptor misfolding in the TNF receptor 1-associated periodic fever syndrome. Arthritis Res Ther 2007, 9:217.
20. Naismith J.H., Devine T.Q., Brandhuber B.J., Sprang S.R. Crystallographic evidence for dimerization of unliganded tumor necrosis factor receptor. J Biol Chem 1995, 270:13303-13307.
21. Baud V., Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001, 11:372-377.
22. Porteu F., Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophilis. J Exp Med 1990, 172:599-607.
23. Kallinich T., Briese S., Roesler J., Rudolph B., Sarioglu N., Blankenstein O., et al. Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis. J Rheumatol 2004, 31:2519-2522.
24. Stojanov S., Dejaco C., Lohse P., Huss K., Duftner C., Belohradsky B.H., et al. Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Ann Rheum Dis 2008, 67:1292-1298.
25. D'Osualdo A., Ferlito F., Prigione I., Obici L., Meini A., Zulian F., et al. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum 2006, 54:998-1008.
26. Churchman S.M., Church L.D., Savic S., Coulthard L.R., Hayward B., Nedjai B., et al. A novel TNFRSF1A splice mutation associated with increased nuclear factor kappaB (NF- kappaB) transcription factor activation in patients with tumour necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis 2008, 67:1589-1595.
27. Lobito A.A., Kimberley F.C., Muppidi J.R., Komarow H., Jackson A.J., Hull K.M., et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006, 108:1320-1327.
28. Siebert S., Fielding C.A., Williams B.D., Brennan P. Mutations of the extracellular domain of tumour necrosis factor receptor I causes reduced NF-κB activation due to decreased surface expression. FEBS Lett 2005, 579:5193-5198.
29. Simon A., Park H., Maddipati R., Lobito A.A., Bulua A.C., Jackson A.J., et al. Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc Natl Acad Sci U S A 2010, 107:9801-9806.
30. Bulua A.C., Simon A., Maddipati R., Pelletier M., Park H., Kim K.Y., et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 2011, 208:519-533.
31. Schmaltz R., Vogt T., Reichrath J. Skin manifestations in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Dermatoendocrinol 2010, 2:26-29.
32. Hull K.M., Wong K., Wood G.M., Chu W.S., Kastner D.L. Monocytic fasciitis: a newly recognized clinical feature of tumor necrosis factor receptor dysfunction. Arthritis Rheum 2002, 46:2189-2194.
33. Aganna E., Martinon F., Hawkins P.N., Ross J.B., Swan D.C., Booth D.R., et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with abroad phenotype including recurrent fever, cold sensitivity, sensorineural, deafness, and AA amyloidosis. Arthritis Rheum 2002, 46:2445-2452.
34. Cantarini L., Iacoponi F., Lucherini O.M., Obici L., Brizi M.G., Cimaz R., et al. Validation of a diagnostic score for the diagnosis of autoinflammatory diseases in adults. Int J Immunopathol Pharmacol 2011, 24:695-702.
35. Cantarini L., Lucherini O.M., Brucato A., Barone L., Cumetti D., Iacoponi F., et al. Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clin Res Cardiol 2012, [Epub ahead of print].
36. Lago F., Dieguez C., Gómez-Reino J., Gualillo O. Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 2007, 3:716-724.
37. Cantarini L., Rigante D., Lucherini O.M., Cimaz R., Laghi Pasini F., Baldari C.T., et al. Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature. Int J Immunopathol Pharmacol 2010, 23:701-707.
38. Cantarini L., Rigante D., Brizi M.G., Lucherini O.M., Sebastiani G.D., Vitale A., et al. Clinical and biochemical landmarks in systemic autoinflammatory diseases. Ann Med 2011, [Epub ahead of print].
39. Nowlan M.L., Drewe E., Bulsara H., Esposito N., Robins R.A., Tighe P.J., et al. Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology (Oxford) 2006, 45:31-37.
40. Nedjai B., Hitman G.A., Quillinan N., Coughlan R.J., Church L., McDermott M.F., et al. Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2009, 60:619-625.
41. Bulua A.C., Mogul D.B., Aksentijevich I., Singh H., He D., Muenz L., et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Arthritis Rheum 2011, [Epub ahead of print].
42. Scallon B., Cai A., Solowski N., Rosenberg A., Song X.Y., Shealy D., et al. Binding and functional comparison of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002, 301:418-426.
43. Arostegui J.I., Solis P., Aldea A., Cantero T., Rius J., Bahíllo P., et al. Etanercept plus colchicine treatment in a child with tumour necrosis factor receptor-associated periodic syndrome abolishes auto-inflammatory episodes without normalizing the subclinical acute phase response. Eur J Pediatr 2005, 164:13-16.
44. Stojanov S., Dejaco C., Lohse P., Huss K., Duftner C., Belohradsky B.H., et al. Clinical and functional characterization of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Ann Rheum Dis 2008, 67:1292-1298.
45. Drewe E., McDermott E.M., Powell P.T., Isaacs J.D., Powell R.J. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford) 2003, 42:235-239.
46. Jesus A.A., Oliveira J.B., Aksentijevich I., Fujihira E., Carneiro-Sampaio M.M., Duarte A.J., et al. TNF receptor-associated periodic syndrome (TRAPS): description of a novel TNFRSF1A mutation and response to etanercept. Eur J Pediatr 2008, 167:1421-1425.
47. Jacobelli S., André M., Alexandra J.F., Dodé C., Papo T. Failure of anti-TNFtherapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS). Rheumatology (Oxford) 2007, 46:1211-1212.
48. Vaitla P.M., Radford P.M., Tighe P.J., Powell R.J., McDermott E.M., Todd I., et al. Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum 2011, 63:1151-1155.
49. Gattorno M., Pelagatti M.A., Meini A., Obici L., Barcellona R., Federici S., et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008, 58:1516-1520.
50. Obici L., Meini A., Cattalini M., Chicca S., Galliani M., Donadei S., et al. Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Ann Rheum Dis 2011, 70:1511-1512.
51. Quillianan N., Mannion G., Mohammad A., Coughlan R., Dickie L.J., McDermott M.F., et al. Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome. Ann Rheum Dis 2011, 70:1692-1693.
52. Martinon F., Chen X., Lee A.H., Glimcher L.H. TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages. Nat Immunol 2010, 11:411-418.